This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Glossary
- ALS=
- amyotrophic lateral sclerosis;
- AMPA=
- α-amino-3-hydroxy-5-methyl-4-isoxazole propionate;
- ATP=
- adenosine triphosphate;
- CBP=
- CREB-binding protein;
- COX=
- cytochrome c oxidase;
- CREB=
- cAMP-response-element-binding protein;
- EPO=
- erythropoietin;
- EPOR=
- EPO receptor;
- FIH=
- factor inhibiting HIF;
- GLUT-1=
- glucose transporter-1;
- HIF=
- hypoxia-induced factor;
- HRE=
- hypoxia-regulated element;
- IDH=
- isocitrate dehydrogenase;
- NADPH=
- nicotine-adenine nucleotide phosphate;
- NFκB=
- nuclear factor kappa B;
- NOS=
- nitric oxide synthase;
- NP=
- neuropilin;
- PHD=
- prolyl hydroxylase domain enzyme;
- PI3K/Akt=
- phosphatidylinositol 3′kinase-Akt;
- POEMS=
- polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes;
- ROS=
- reactive oxygen species;
- Ub=
- ubiquitin;
- VEGF=
- vascular endothelial growth factor;
- VEGFR=
- VEGF receptor;
- VHL=
- von Hippel–Lindau.
GLOSSARY
Oxygen is the final electron acceptor in the aerobic metabolism of glucose that generates adenosine triphosphate (ATP), the source of energy for most active cellular processes. Cells have a rapid and efficient molecular response system that senses hypoxia and triggers an evolutionarily conserved pathway mediated by hypoxia-induced factor (HIF). This transcriptional regulator promotes induction of several adaptive genes that facilitate oxygen supply and support anaerobic ATP production. These genes include those encoding for glucose transporter-1 (GLUT-1), glycolytic enzymes, vascular endothelial growth factor (VEGF), and erythropoietin (EPO). During normoxia, the product of the von Hippel–Lindau (VHL) tumor suppressor gene binds to HIF and triggers its ubiquitin-mediated proteolysis. Whereas the hypoxia response has a critical adaptive role in normal cell functioning, its multiple effectors have also been implicated either in the pathogenesis or as neuroprotective factors in several neurologic disorders, including hemangioblastoma, malignant glioma, and cerebral ischemia. Both the VEGF and EPO signaling pathways are potential therapeutic targets in these and other conditions. There are several excellent reviews on all these topics.1–15
CELLULAR OXYGEN SENSING MECHANISMS
Hypoxia-inducible factor and oxygen sensing.
HIFs are transcription factors that bind to canonical DNA sequences called hypoxia-regulated elements. These factors activate the expression of many genes encoding proteins that regulate cell metabolism, angiogenesis, vascular tone, erythropoiesis, and other functions.1–3 HIF is a heterodimeric DNA-binding complex composed of one hypoxia-inducible HIFα-subunit (HIF1α or HIF2α) and a constitutive non-oxygen-responsive subunit HIF1β.1–3 The HIF pathway is regulated by oxygen-dependent posttranslational hydroxylation of HIFα, which results in its rapid inactivation and degradation during normoxia (figure 1). HIFα subunits are substrates of a family of oxygen-dependent enzymes, including prolyl hydroxylase domain enzymes (PHDs) and aspargyl hydroxylase (factor inhibiting HIF, FIH). These enzymes act as oxygen sensors and catalyze the hydroxylation of HIFα at specific residues during normoxic conditions.1–4 These hydroxylases utilize molecular oxygen and require ferrous …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
